Favipiravir in the Treatment of Outpatient COVID-19: A Multicenter, Randomized, Triple-Blind, Placebo-Controlled Clinical Trial
Atefeh Vaezi, Mehrzad Salmasi, Forogh Soltaninejad, Mehrdad Salahi, Shaghayegh Haghjooy Javanmard, Babak Amra
Advances in Respiratory Medicine, doi:10.3390/arm91010004
What are the main findings?
• Favipiravir, an RNA-dependent RNA polymerase inhibitor, shows no benefit in preventing the hospitalization of mild to moderate COVID-19 patients. What is the implication of the main finding?
• Our results may inform decisions on the exclusion of Favipiravir from mild to moderate COVID-19 treatment guidelines.
Informed Consent Statement: Patients were informed about the study protocol and objectives and were asked to sign an informed consent before participation. All data were managed, analyzed, and reported anonymously. Medications were provided by the research team and imposed no costs on patients.
Conflicts of Interest: The authors declare that they have no conflict of interest.
References
Alqahtani, Kumar, Aljawder, Abdulrahman, Mohamed et al., Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease, Sci. Rep,
doi:10.1038/s41598-022-08794-wBaranovich, Wong, Armstrong, Marjuki, Webby et al., T-705 (Favipiravir) Induces Lethal Mutagenesis in Influenza A H1N1 Viruses In Vitro, J. Virol,
doi:10.1128/JVI.02346-12Bosaeed, Alharbi, Mahmoud, Alrehily, Bahlaq et al., Efficacy of favipiravir in adults with mild COVID-19: A randomized, double-blind, multicentre, placebocontrolled clinical trial, Clin. Microbiol. Infect,
doi:10.1016/j.cmi.2021.12.026Bryant, Lawrie, Fordham, Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines, Am. J. Ther,
doi:10.1097/MJT.0000000000001402Cai, Yang, Liu, Chen, Shu et al., Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study, Engineering,
doi:10.1016/j.eng.2020.03.007Darab, Keshavarz, Sadeghi, Shahmohamadi, Kavosi, The economic burden of coronavirus disease 2019 (COVID-19): Evidence from Iran, BMC Health Serv. Res
Deng, Yang, Yang, Chen, Qiu et al., Evaluation of favipiravir in the treatment of COVID-19 based on the real-world, Expert Rev. Anti-Infect. Ther,
doi:10.1080/14787210.2022.2012155Dessie, Zewotir, Mortality-related risk factors of COVID-19: A systematic review and meta-analysis of 42 studies and 423,117 patients, BMC Infect. Dis,
doi:10.1186/s12879-021-06536-3Frediansyah, Nainu, Dhama, Mudatsir, Harapan, Remdesivir and its antiviral activity against COVID-19: A systematic review, Clin. Epidemiology Glob. Health,
doi:10.1016/j.cegh.2020.07.011Gonçalves, Bertrand, Ke, Comets, De Lamballerie et al., Timing of antiviral treatment initiation is critical to reduce SARS-CoV-2 viral load. CPT Pharmacomet, Syst. Pharmacol,
doi:10.1002/psp4.12543Goyal, Cardozo-Ojeda, Schiffer, Potency and timing of antiviral therapy as determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory response, Sci. Adv,
doi:10.1126/sciadv.abc7112Hassaniazad, Farshidi, Gharibzadeh, Bazram, Khalili et al., Efficacy and safety of favipiravir plus interferon-beta versus lopinavir/ritonavir plus interferon-beta in moderately ill patients with COVID-19: A randomized clinical trial, J. Med. Virol,
doi:10.1002/jmv.27724Hassanipour, Arab-Zozani, Amani, Heidarzad, Fathalipour et al., Addendum: The efficacy and safety of Favipiravir in treatment of COVID-19: A systematic review and meta-analysis of clinical trials, Sci. Rep
Ivashchenko, Dmitriev, Vostokova, Azarova, Blinow et al., AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial, Clin. Infect. Dis
Khamis, Al Naabi, Al Lawati, Ambusaidi, Al Sharji et al., Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia, Int. J. Infect. Dis,
doi:10.1016/j.ijid.2020.11.008Pan, Peto, Henao-Restrepo, Preziosi, Sathiyamoorthy et al., Repurposed Antiviral Drugs for COVID-19-Interim WHO Solidarity Trial Results, N. Engl. J. Med
Reddy, Patil, Khobragade, Balki, Raj et al., Evaluation of the Safety and Efficacy of Favipiravir in Adult Indian Patients with Mild-to-Moderate COVID-19 in a Real-World Setting, Int. J. Gen. Med,
doi:10.2147/IJGM.S349241Schulz, Altman, Moher, Consort, statement: Updated guidelines for reporting parallel group randomised trials, J. Pharmacol. Pharmacother,
doi:10.4103/0976-500X.72352Shrestha, Budhathoki, Khadka, Shah, Pokharel et al., Favipiravir versus other antiviral or standard of care for COVID-19 treatment: A rapid systematic review and meta-analysis, Virol. J,
doi:10.1186/s12985-020-01412-zSirijatuphat, Manosuthi, Niyomnaitham, Owen, Copeland et al., Early treatment of Favipiravir in COVID-19 patients without pneumonia: A multicentre, open-labelled, randomized control study, Emerg. Microbes Infect,
doi:10.1080/22221751.2022.2117092Solaymani-Dodaran, Ghanei, Bagheri, Qazvini, Vahedi et al., Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia, Int. Immunopharmacol,
doi:10.1016/j.intimp.2021.107522Soy, Keser, Atagündüz, Tabak, Atagündüz et al., Cytokine storm in COVID-19: Pathogenesis and overview of anti-inflammatory agents used in treatment, Clin. Rheumatol,
doi:10.1007/s10067-020-05190-5Worldometer, COVID-19 Pandemic
{ 'indexed': {'date-parts': [[2023, 1, 31]], 'date-time': '2023-01-31T06:18:41Z', 'timestamp': 1675145921178},
'reference-count': 26,
'publisher': 'MDPI AG',
'issue': '1',
'license': [ { 'start': { 'date-parts': [[2023, 1, 28]],
'date-time': '2023-01-28T00:00:00Z',
'timestamp': 1674864000000},
'content-version': 'vor',
'delay-in-days': 0,
'URL': 'https://creativecommons.org/licenses/by/4.0/'}],
'funder': [{'name': 'Isfahan University of Medical Sciences'}],
'content-domain': {'domain': [], 'crossmark-restriction': False},
'abstract': '<jats:p>Background: Finding effective outpatient treatments to prevent COVID-19 progression '
'and hospitalization is necessary and is helpful in managing limited hospital resources. '
'Repurposing previously existing treatments is highly desirable. In this study, we evaluate '
'the efficacy of Favipiravir in the prevention of hospitalization in symptomatic COVID-19 '
'patients who were not eligible for hospitalization. Methods: This study was a triple-blind '
'randomized controlled trial conducted between 5 December 2020 and 31 March 2021 in three '
'outpatient centers in Isfahan, Iran. Patients in the intervention group received Favipiravir '
'1600 mg daily for five days, and the control group received a placebo. Our primary outcome '
'was the proportion of hospitalized participants from day 0 to day 28. The outcome was '
'assessed on days 3, 7, 14, 21, and 28 through phone calls. Results: Seventy-seven patients '
'were randomly allocated to Favipiravir and placebo groups. There was no significant '
'difference between groups considering baseline characteristics. During the study period, '
'10.5% of patients in the Favipiravir group and 5.1% of patients in the placebo group were '
'hospitalized, but there was no significant difference between them (p-value = 0.3). No '
'adverse event was reported in the treatment group. Conclusions: Our study shows that '
'Favipiravir did not reduce the hospitalization rate of mild to moderate COVID-19 patients in '
'outpatient settings.</jats:p>',
'DOI': '10.3390/arm91010004',
'type': 'journal-article',
'created': {'date-parts': [[2023, 1, 30]], 'date-time': '2023-01-30T16:25:47Z', 'timestamp': 1675095947000},
'page': '18-25',
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': 'Favipiravir in the Treatment of Outpatient COVID-19: A Multicenter, Randomized, Triple-Blind, '
'Placebo-Controlled Clinical Trial',
'prefix': '10.3390',
'volume': '91',
'author': [ { 'ORCID': 'http://orcid.org/0000-0002-1829-0494',
'authenticated-orcid': False,
'given': 'Atefeh',
'family': 'Vaezi',
'sequence': 'first',
'affiliation': [ { 'name': 'Cancer Prevention Research Center, Isfahan University of Medical '
'Sciences, Isfahan 8174673461, Iran'}]},
{ 'given': 'Mehrzad',
'family': 'Salmasi',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Internal Medicine, School of Medicine, Isfahan '
'University of Medical Sciences, Isfahan 8174673461, Iran'}]},
{ 'given': 'Forogh',
'family': 'Soltaninejad',
'sequence': 'additional',
'affiliation': [ { 'name': 'Bamdad Respiratory and Sleep Research Center, Department of '
'Internal Medicine, School of Medicine, Isfahan University of '
'Medical Sciences, Isfahan 8174673461, Iran'}]},
{ 'given': 'Mehrdad',
'family': 'Salahi',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Infectious Disease, School of Medicine, Isfahan '
'University of Medical Sciences, Isfahan 8174673461, Iran'}]},
{ 'given': 'Shaghayegh Haghjooy',
'family': 'Javanmard',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Physiology, Applied Physiology Research Center, '
'Cardiovascular Research Institute, Isfahan University of Medical '
'Sciences, Isfahan 8174673461, Iran'}]},
{ 'ORCID': 'http://orcid.org/0000-0001-9606-7434',
'authenticated-orcid': False,
'given': 'Babak',
'family': 'Amra',
'sequence': 'additional',
'affiliation': [ { 'name': 'Bamdad Respiratory and Sleep Research Center, Department of '
'Internal Medicine, School of Medicine, Isfahan University of '
'Medical Sciences, Isfahan 8174673461, Iran'}]}],
'member': '1968',
'published-online': {'date-parts': [[2023, 1, 28]]},
'reference': [ { 'key': 'ref_1',
'unstructured': 'Worldometer (2022, October 01). COVID-19 Pandemic. Available online: '
'https://www.worldometers.info/coronavirus/.'},
{ 'key': 'ref_2',
'doi-asserted-by': 'crossref',
'unstructured': 'Dessie, Z.G., and Zewotir, T. (2021). Mortality-related risk factors of '
'COVID-19: A systematic review and meta-analysis of 42 studies and '
'423,117 patients. BMC Infect. Dis., 21.',
'DOI': '10.1186/s12879-021-06536-3'},
{ 'key': 'ref_3',
'first-page': '1',
'article-title': 'The economic burden of coronavirus disease 2019 (COVID-19): Evidence '
'from Iran',
'volume': '21',
'author': 'Darab',
'year': '2021',
'journal-title': 'BMC Health Serv. Res.'},
{ 'key': 'ref_4',
'doi-asserted-by': 'crossref',
'first-page': 'eabc7112',
'DOI': '10.1126/sciadv.abc7112',
'article-title': 'Potency and timing of antiviral therapy as determinants of duration of '
'SARS-CoV-2 shedding and intensity of inflammatory response',
'volume': '6',
'author': 'Goyal',
'year': '2020',
'journal-title': 'Sci. Adv.'},
{ 'key': 'ref_5',
'doi-asserted-by': 'crossref',
'first-page': '509',
'DOI': '10.1002/psp4.12543',
'article-title': 'Timing of antiviral treatment initiation is critical to reduce '
'SARS-CoV-2 viral load',
'volume': '9',
'author': 'Bertrand',
'year': '2020',
'journal-title': 'CPT Pharmacomet. Syst. Pharmacol.'},
{ 'key': 'ref_6',
'doi-asserted-by': 'crossref',
'first-page': '2085',
'DOI': '10.1007/s10067-020-05190-5',
'article-title': 'Cytokine storm in COVID-19: Pathogenesis and overview of '
'anti-inflammatory agents used in treatment',
'volume': '39',
'author': 'Soy',
'year': '2020',
'journal-title': 'Clin. Rheumatol.'},
{ 'key': 'ref_7',
'doi-asserted-by': 'crossref',
'first-page': 'e434',
'DOI': '10.1097/MJT.0000000000001402',
'article-title': 'Ivermectin for Prevention and Treatment of COVID-19 Infection: A '
'Systematic Review, Meta-analysis, and Trial Sequential Analysis to '
'Inform Clinical Guidelines',
'volume': '28',
'author': 'Bryant',
'year': '2021',
'journal-title': 'Am. J. Ther.'},
{ 'key': 'ref_8',
'doi-asserted-by': 'crossref',
'first-page': '123',
'DOI': '10.1016/j.cegh.2020.07.011',
'article-title': 'Remdesivir and its antiviral activity against COVID-19: A systematic '
'review',
'volume': '9',
'author': 'Frediansyah',
'year': '2020',
'journal-title': 'Clin. Epidemiology Glob. Health'},
{ 'key': 'ref_9',
'doi-asserted-by': 'crossref',
'first-page': '497',
'DOI': '10.1056/NEJMoa2023184',
'article-title': 'Repurposed Antiviral Drugs for COVID-19—Interim WHO Solidarity Trial '
'Results',
'volume': '384',
'author': 'Pan',
'year': '2021',
'journal-title': 'N. Engl. J. Med.'},
{ 'key': 'ref_10',
'doi-asserted-by': 'crossref',
'first-page': '1996',
'DOI': '10.1038/s41598-022-05835-2',
'article-title': 'Addendum: The efficacy and safety of Favipiravir in treatment of '
'COVID-19: A systematic review and meta-analysis of clinical trials',
'volume': '12',
'author': 'Hassanipour',
'year': '2022',
'journal-title': 'Sci. Rep.'},
{ 'key': 'ref_11',
'doi-asserted-by': 'crossref',
'first-page': '3741',
'DOI': '10.1128/JVI.02346-12',
'article-title': 'T-705 (Favipiravir) Induces Lethal Mutagenesis in Influenza A H1N1 '
'Viruses In Vitro',
'volume': '87',
'author': 'Baranovich',
'year': '2013',
'journal-title': 'J. Virol.'},
{ 'key': 'ref_12',
'doi-asserted-by': 'crossref',
'first-page': '446',
'DOI': '10.1016/j.antiviral.2013.09.015',
'article-title': 'Favipiravir (T-705), a novel viral RNA polymerase inhibitor',
'volume': '100',
'author': 'Furuta',
'year': '2013',
'journal-title': 'Antivir. Res.'},
{ 'key': 'ref_13',
'doi-asserted-by': 'crossref',
'first-page': '1192',
'DOI': '10.1016/j.eng.2020.03.007',
'article-title': 'Experimental Treatment with Favipiravir for COVID-19: An Open-Label '
'Control Study',
'volume': '6',
'author': 'Cai',
'year': '2020',
'journal-title': 'Engineering'},
{ 'key': 'ref_14',
'doi-asserted-by': 'crossref',
'first-page': '107522',
'DOI': '10.1016/j.intimp.2021.107522',
'article-title': 'Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 '
'pneumonia',
'volume': '95',
'author': 'Ghanei',
'year': '2021',
'journal-title': 'Int. Immunopharmacol.'},
{ 'key': 'ref_15',
'doi-asserted-by': 'crossref',
'first-page': '100',
'DOI': '10.4103/0976-500X.72352',
'article-title': 'CONSORT 2010 statement: Updated guidelines for reporting parallel group '
'randomised trials',
'volume': '1',
'author': 'Schulz',
'year': '2010',
'journal-title': 'J. Pharmacol. Pharmacother.'},
{ 'key': 'ref_16',
'doi-asserted-by': 'crossref',
'first-page': '3184',
'DOI': '10.1002/jmv.27724',
'article-title': 'Efficacy and safety of favipiravir plus interferon-beta versus '
'lopinavir/ritonavir plus interferon-beta in moderately ill patients '
'with COVID-19: A randomized clinical trial',
'volume': '94',
'author': 'Hassaniazad',
'year': '2022',
'journal-title': 'J. Med. Virol.'},
{ 'key': 'ref_17',
'doi-asserted-by': 'crossref',
'first-page': '538',
'DOI': '10.1016/j.ijid.2020.11.008',
'article-title': 'Randomized controlled open label trial on the use of favipiravir '
'combined with inhaled interferon beta-1b in hospitalized patients with '
'moderate to severe COVID-19 pneumonia',
'volume': '102',
'author': 'Khamis',
'year': '2021',
'journal-title': 'Int. J. Infect. Dis.'},
{ 'key': 'ref_18',
'doi-asserted-by': 'crossref',
'first-page': '4925',
'DOI': '10.1038/s41598-022-08794-w',
'article-title': 'Randomized controlled trial of favipiravir, hydroxychloroquine, and '
'standard care in patients with mild/moderate COVID-19 disease',
'volume': '12',
'author': 'AlQahtani',
'year': '2022',
'journal-title': 'Sci. Rep.'},
{ 'key': 'ref_19',
'doi-asserted-by': 'crossref',
'first-page': '531',
'DOI': '10.1093/cid/ciaa1176',
'article-title': 'AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease '
'2019 (COVID-19): Interim Results of a Phase II/III Multicenter '
'Randomized Clinical Trial',
'volume': '73',
'author': 'Ivashchenko',
'year': '2021',
'journal-title': 'Clin. Infect. Dis.'},
{ 'key': 'ref_20',
'doi-asserted-by': 'crossref',
'first-page': '2197',
'DOI': '10.1080/22221751.2022.2117092',
'article-title': 'Early treatment of Favipiravir in COVID-19 patients without pneumonia: '
'A multicentre, open-labelled, randomized control study',
'volume': '11',
'author': 'Sirijatuphat',
'year': '2022',
'journal-title': 'Emerg. Microbes Infect.'},
{ 'key': 'ref_21',
'doi-asserted-by': 'crossref',
'first-page': '602',
'DOI': '10.1016/j.cmi.2021.12.026',
'article-title': 'Efficacy of favipiravir in adults with mild COVID-19: A randomized, '
'double-blind, multicentre, placebo-controlled clinical trial',
'volume': '28',
'author': 'Bosaeed',
'year': '2022',
'journal-title': 'Clin. Microbiol. Infect.'},
{ 'key': 'ref_22',
'doi-asserted-by': 'crossref',
'first-page': '555',
'DOI': '10.1080/14787210.2022.2012155',
'article-title': 'Evaluation of favipiravir in the treatment of COVID-19 based on the '
'real-world',
'volume': '20',
'author': 'Deng',
'year': '2022',
'journal-title': 'Expert Rev. Anti-Infect. Ther.'},
{ 'key': 'ref_23',
'doi-asserted-by': 'crossref',
'first-page': '141',
'DOI': '10.1186/s12985-020-01412-z',
'article-title': 'Favipiravir versus other antiviral or standard of care for COVID-19 '
'treatment: A rapid systematic review and meta-analysis',
'volume': '17',
'author': 'Shrestha',
'year': '2020',
'journal-title': 'Virol. J.'},
{ 'key': 'ref_24',
'doi-asserted-by': 'crossref',
'first-page': '108455',
'DOI': '10.1016/j.intimp.2021.108455',
'article-title': 'Future of antivirals in COVID-19: The case of favipiravir',
'volume': '103',
'author': 'Kow',
'year': '2022',
'journal-title': 'Int. Immunopharmacol.'},
{ 'key': 'ref_25',
'doi-asserted-by': 'crossref',
'first-page': '4551',
'DOI': '10.2147/IJGM.S349241',
'article-title': 'Evaluation of the Safety and Efficacy of Favipiravir in Adult Indian '
'Patients with Mild-to-Moderate COVID-19 in a Real-World Setting',
'volume': '15',
'author': 'Reddy',
'year': '2022',
'journal-title': 'Int. J. Gen. Med.'},
{ 'key': 'ref_26',
'doi-asserted-by': 'crossref',
'first-page': '501',
'DOI': '10.1016/j.ijid.2020.10.069',
'article-title': 'Role of favipiravir in the treatment of COVID-19',
'volume': '102',
'author': 'Joshi',
'year': '2021',
'journal-title': 'Int. J. Infect. Dis.'}],
'container-title': 'Advances in Respiratory Medicine',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://www.mdpi.com/2543-6031/91/1/4/pdf',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2023, 1, 30]],
'date-time': '2023-01-30T18:19:29Z',
'timestamp': 1675102769000},
'score': 1,
'resource': {'primary': {'URL': 'https://www.mdpi.com/2543-6031/91/1/4'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2023, 1, 28]]},
'references-count': 26,
'journal-issue': {'issue': '1', 'published-online': {'date-parts': [[2023, 2]]}},
'alternative-id': ['arm91010004'],
'URL': 'http://dx.doi.org/10.3390/arm91010004',
'relation': {},
'ISSN': ['2543-6031'],
'subject': ['Pulmonary and Respiratory Medicine'],
'container-title-short': 'Advances in Respiratory Medicine',
'published': {'date-parts': [[2023, 1, 28]]}}
